Holen Sie sich die Stockscreener-App
0.50
0.00%
0.00
Vorhandelsmarkt:
.54
0.04
+8.00%
Schlusskurs vom Vortag:
$0.50
Offen:
$0.51
24-Stunden-Volumen:
192.77K
Relative Volume:
0.18
Marktkapitalisierung:
$4.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.71M
KGV:
-0.0427
EPS:
-11.71
Netto-Cashflow:
$-18.24M
1W Leistung:
-18.03%
1M Leistung:
-42.86%
6M Leistung:
-64.54%
1J Leistung:
-91.67%
1-Tages-Spanne:
$0.4913
$0.529
1-Wochen-Bereich:
$0.4711
$0.65
52-Wochen-Spanne:
$0.2806
$5.80
Genprex Inc Stock (GNPX) Company Profile
Firmenname
Genprex Inc
Sektor
Branche
Telefon
512-537-7997
Adresse
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Vergleichen Sie GNPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.50 | 4.25M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-26 | Eingeleitet | National Securities | Buy |
| 2019-04-29 | Eingeleitet | Noble Capital Markets | Outperform |
Genprex Inc Aktie (GNPX) Neueste Nachrichten
Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Genprex Inc (NASDAQ: GNPX): An Enticing Stock To Watch - Stocks Register
Genprex doses first subject in expansion part of lung cancer gene therapy trial - Clinical Trials Arena
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire
Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs - Defense World
Genprex Advances Cancer Trials and Diabetes Therapy - Yahoo Finance
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
SEC Form 424B5 filed by Genprex Inc. - Quantisnow
Genprex Completes Phase 1 Dose Escalation of Acclaim-3 Clinical Trial for ES-SCLC PatientsGenprex, Inc. (NASDAQ:GNPX) announced in a press release dated December 16, 2024, the successful completion of the Phase 1 dose escalation segment of the - Defense World
Genprex advances to phase 2 in lung cancer trial - Investing.com
Genprex's Reqorsa Advances to Phase 2 After Successful Safety Trial in Lung Cancer Treatment - StockTitan
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences - The Eastern Progress Online
Genprex to Participate in 2024 BIO Europe Conference - The Eastern Progress Online
Genprex Collaborators Present Positive Preclinical Data on the U - GuruFocus.com
Genprex Collaborators to Present Positive Preclinical Data on th - GuruFocus.com
Genprex links with University of Michigan on lung cancer treatment - Yahoo Finance
Genprex secures exclusive gene therapy license for cancer By Investing.com - Investing.com Canada
Genprex secures exclusive gene therapy license for cancer - Investing.com India
Genprex Secures Global Patent Rights for Breakthrough Lung Cancer Gene Therapy | GNPX Stock News - StockTitan
Genprex faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Genprex faces Nasdaq delisting over equity shortfall - Investing.com India
U.S. Stock market top gainers: Mullen Automotive gains 92.92% while Genprex increases by 54.48% during mid day trading - Business Upturn
'Animal spirits' set to drive S&P 500 to 6,600 by mid-2025, Evercore says - Investing.com
Genprex reports promising preclinical data on cancer therapy - Investing.com
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - BioSpace
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Thera - GuruFocus.com
Genprex regains Nasdaq compliance with bid price rule - Investing.com India
Genprex regains Nasdaq compliance with bid price rule By Investing.com - Investing.com Australia
Genprex reports promising preclinical data on cancer therapy By Investing.com - Investing.com UK
Genprex Announces Sponsored Research Agreement with The Universi - GuruFocus.com
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Increases By 5.2% - Defense World
Investor Excitement Sparks Genprex (GNPX) Stock Rally - Stocks Telegraph
Genprex reports positive preclinical gene therapy data By Investing.com - Investing.com South Africa
Genprex reports positive preclinical gene therapy data - Investing.com India
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma - The Malaysian Reserve
Genprex (NASDAQ:GNPX) Announces Sponsored Research Agreement with University of Michigan Rogel Cancer Center for Study on TUSC2 Gene Therapy in ALK-Positive Lung Cancer Patients - Defense World
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.80% - MSN
Genprex explores gene therapy in lung cancer study - Investing.com India
Genprex explores gene therapy in lung cancer study By Investing.com - Investing.com South Africa
Genprex signs two lung cancer research agreements - TipRanks
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive - StreetInsider.com
Finanzdaten der Genprex Inc-Aktie (GNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):